RA Capital

Abcuro

abcuro.com

Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease, together with ex-vivo validation in diseased tissue, has uncovered new approaches to target key compartments of the immune system.